放射性皮膚炎市場規模、佔有率和成長分析（按產品、分銷管道和地區）- 2025-2032 年產業預測

Radiodermatitis Market Size, Share, Growth Analysis, By Product (Topical, Oral Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2025-2032

出版日期: 2025年01月09日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球放射性皮膚炎市場規模價值為 4.5236 億美元，預計將從 2024 年的 4.7091 億美元成長到 2032 年的 6.4944 億美元，預測期內（2025-2032 年）的複合年成長率為 4.1%。

放射性皮膚炎市場因放射線治療相關皮膚問題的影響而呈上升趨勢，95%的癌症患者，包括85-95%的乳癌患者，都患有各種形式的放射性皮膚炎。 COVID-19 疫情最初將資源重新轉向疫情護理並減少了放射治療次數，從而阻礙了市場成長，然而，監管的放寬促進了腫瘤服務的復甦。此外，糖尿病和肥胖症盛行率的上升預計將導致癌症病例的增加，到 2030 年預計糖尿病患者將達到 12 億。此類患者的數量增加，尤其是患有併發症的患者，可能會加劇放射性皮膚併發症，並為未來幾年放射性皮膚炎市場提供寶貴的機會。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分析市場佔有率
- 收益與前一年同期比較（2022-2024 年）

主要企業簡介

3M Company（United States）
Smith & Nephew plc（United Kingdom）
Investor AB（Molnlycke Health Care AB）（Sweden）
BMG Pharma SpA（Italy）
Stratpharma Inc.（Switzerland）
Bausch Health Companies Inc.（Canada）
Bayer AG（Germany）
Paul Hartmann AG（Germany）
KeraNetics, Inc.（United States）
Charles River Laboratories（United States）
The Jackson Laboratory（United States）
InterMed SA（Greece）
AceTech（South Korea）
KCI Licensing Inc.（Acelity）（United States）
Derma Sciences Inc.（Integra LifeSciences）（United States）
Ligand Pharmaceuticals Inc.（Apeiron Biologics）（United States）
Lutris Pharma Ltd.（Israel）
GlaxoSmithKline plc（United Kingdom）
ConvaTec Group plc（United Kingdom）
Viatris Inc（United States）

結論和建議

簡介目錄

Product Code: SQMIG35G2240

Global Radiodermatitis Market size was valued at USD 452.36 million in 2023 and is poised to grow from USD 470.91 million in 2024 to USD 649.44 million by 2032, growing at a CAGR of 4.1% during the forecast period (2025-2032).

The radiodermatitis treatment market is witnessing heightened demand due to the significant impact of radiation therapy-related skin issues, with 95% of cancer patients, including 85-95% of breast cancer patients, affected by varying forms of radiodermatitis. Although the COVID-19 pandemic initially obstructed market growth by diverting resources to pandemic care and reducing radiation therapy sessions, the easing of restrictions has facilitated a resurgence in oncology services. Moreover, the rising prevalence of diabetes and obesity is expected to increase cancer cases, with projections estimating 1.2 billion diabetes cases by 2030. This growing patient population, particularly those with co-morbidities, will likely exacerbate radiation-induced skin complications and generate valuable opportunities in the radiodermatitis treatment market moving forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Radiodermatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Radiodermatitis Market Segmental Analysis

Global Radiodermatitis Market is segmented by Product, Distribution Channel and region. Based on Product, the market is segmented into Topical, Oral Drugs and Dressings. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Radiodermatitis Market

One of the primary drivers of the global radiodermatitis market is the rising utilization of radiation therapy in cancer treatments. As more patients undergo radiation therapy as part of their oncology care, the prevalence of radiodermatitis, a common side effect associated with such treatments, is also on the rise. This surge in cases necessitates a corresponding increase in the availability and development of effective treatments and management options for radiodermatitis. Consequently, the expanding recognition of radiation therapy's role in cancer management directly fuels the growth of the radiodermatitis market, reflecting the urgent need for addressing the associated skin complications.

Restraints in the Global Radiodermatitis Market

The global radiodermatitis market faces significant restraints primarily due to the side effects and adverse reactions associated with various treatment options. These complications can restrict the applicability of certain therapies within specific patient populations, leading to hesitancy among healthcare providers and patients alike. Such concerns about safety and tolerability may inhibit the widespread adoption of some treatment modalities, consequently impacting the overall growth potential of the market. As a result, addressing these limitations is crucial for the advancement and acceptance of innovative therapies aimed at effectively managing radiodermatitis.

Market Trends of the Global Radiodermatitis Market

The Global Radiodermatitis market is experiencing a notable shift towards the adoption of advanced treatment options, reflecting a significant trend in patient care management. Innovative therapies, including advanced topical products and specialized dressings, are increasingly sought after for their efficacy in alleviating radiation-induced skin damage. As healthcare providers recognize the importance of enhancing patient quality of life during cancer treatments, the demand for these advanced solutions is projected to rise. This trend is further fueled by ongoing research and development, resulting in more targeted treatments that address the complexities of radiodermatitis, ultimately driving market growth and diversification.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Technology Assessment
Patent Analysis
Pipeline Analysis

Global Radiodermatitis Market Size by Product & CAGR (2025-2032)

Market Overview
Topical
- Corticosteroids
- Hydrophilic Creams
- Antibiotics
- Others
Oral Drugs
Dressings
- Hydrogel & Hydrocolloid dressings
- No Sting Barrier Film
- Honey-impregnated Gauze
- Silicone Coated Dressings
- Others

Global Radiodermatitis Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Radiodermatitis Market Size & CAGR (2025-2032)

North America (Product, Distribution Channel)
- US
- Canada
Europe (Product, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

3M Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Smith & Nephew plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Investor AB (Molnlycke Health Care AB) (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BMG Pharma S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stratpharma Inc. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Paul Hartmann AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KeraNetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
The Jackson Laboratory (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InterMed S.A. (Greece)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AceTech (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KCI Licensing Inc. (Acelity) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Derma Sciences Inc. (Integra LifeSciences) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ligand Pharmaceuticals Inc. (Apeiron Biologics) (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lutris Pharma Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ConvaTec Group plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments